Geometric mean fold rise (GMFR) of Omicron-Specific Antibody (For Part J only) at Day 15;Geometric Mean Titer (GMT) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific Antibody at Day 29;GMT of Omicron-Specific Antibody at Day 91 (For Part G only);GMT of Omicron-Specific Antibody (For Part J only) at Day 15;GMT of Omicron-Specific Antibody (For Parts F, G, H and J only) at Day 29;GMT of SARS-CoV-2-Specific Antibody at Day 91 (For Part G only);Number of Participants with Serious AEs (SAEs), Medically Attended AEs (MAAEs), AEs Leading to Withdrawal, and AEs of Special Interest (AESIs);Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs);Number of Participants with Unsolicited Adverse Events (AEs);Seroresponse Rate of Vaccine Recipients at Day 15 (For Part J only);Seroresponse Rate of Vaccine Recipients at Day 29;Seroresponse Rate of Vaccine Recipients at Day 91 (For Part G only)

Geometric mean fold rise (GMFR) of Omicron-Specific Antibody (For Part J only) at Day 15;Geometric Mean Titer (GMT) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific Antibody at Day 29;GMT of Omicron-Specific Antibody at Day 91 (For Part G only);GMT of Omicron-Specific Antibody (For Part J only) at Day 15;GMT of Omicron-Specific Antibody (For Parts F, G, H and J only) at Day 29;GMT of SARS-CoV-2-Specific Antibody at Day 91 (For Part G only);Number of Participants with Serious AEs (SAEs), Medically Attended AEs (MAAEs), AEs Leading to Withdrawal, and AEs of Special Interest (AESIs);Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs);Number of Participants with Unsolicited Adverse Events (AEs);Seroresponse Rate of Vaccine Recipients at Day 15 (For Part J only);Seroresponse Rate of Vaccine Recipients at Day 29;Seroresponse Rate of Vaccine Recipients at Day 91 (For Part G only)

Geometric Mean Titer (GMT) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific Antibody at Day 29;GMT of Omicron-Specific Antibody at Day 91 (For Part G only);GMT of Omicron-Specific Antibody (For Parts F, G, and H only) at Day 29;GMT of SARS-CoV-2-Specific Antibody at Day 91 (For Part G only);Number of Participants with Serious AEs (SAEs), Medically Attended AEs (MAAEs), AEs Leading to Withdrawal, and AEs of Special Interest (AESIs);Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs);Number of Participants with Unsolicited Adverse Events (AEs);Seroresponse Rate of Vaccine Recipients at Day 29;Seroresponse Rate of Vaccine Recipients at Day 91 (For Part G only)

Geometric Mean Titer (GMT) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific Antibody at Day 29;GMT of Omicron-Specific Antibody at Day 91 (For Part G only);GMT of Omicron-Specific Antibody (For Parts F, G, and H only) at Day 29;GMT of SARS-CoV-2-Specific Antibody at Day 91 (For Part G only);Number of Participants with Serious AEs (SAEs), Medically Attended AEs (MAAEs), AEs Leading to Withdrawal, and AEs of Special Interest (AESIs);Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs);Number of Participants with Unsolicited Adverse Events (AEs);Seroresponse Rate of Vaccine Recipients at Day 29;Seroresponse Rate of Vaccine Recipients at Day 91 (For Part G only)

Geometric Mean Titer (GMT) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific Antibody at Day 29;GMT of Omicron-Specific Antibody at Day 91 (For Part G only);GMT of Omicron-Specific Antibody (For Parts F and G only) at Day 29;GMT of SARS-CoV-2-Specific Antibody at Day 91 (For Part G only);Number of Participants with Serious AEs (SAEs), Medically Attended AEs (MAAEs), AEs Leading to Withdrawal, and AEs of Special Interest (AESIs);Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs);Number of Participants with Unsolicited Adverse Events (AEs);Seroresponse Rate of Vaccine Recipients at Day 29;Seroresponse Rate of Vaccine Recipients at Day 91 (For Part G only)

Geometric Mean Titer (GMT) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific Antibody at Day 29;GMT of Omicron-Specific Antibody at Day 91 (For Part G only);GMT of Omicron-Specific Antibody (For Parts F and G only) at Day 29;GMT of SARS-CoV-2-Specific Antibody at Day 91 (For Part G only);Number of Participants with Serious AEs (SAEs), Medically Attended AEs (MAAEs), AEs Leading to Withdrawal, and AEs of Special Interest (AESIs);Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs);Number of Participants with Unsolicited Adverse Events (AEs);Seroresponse Rate of Vaccine Recipients at Day 29;Seroresponse Rate of Vaccine Recipients at Day 91 (For Part G only)

Geometric Mean Titer (GMT) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific Antibody;Number of Participants with Serious AEs (SAEs), Medically Attended AEs (MAAEs), AEs Leading to Withdrawal, and AEs of Special Interest (AESIs);Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs);Number of Participants with Unsolicited Adverse Events (AEs);Seroresponse Rate of Vaccine Recipients

Geometric Mean Titer (GMT) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific Antibody;Number of Participants with Serious AEs (SAEs), Medically Attended AEs (MAAEs), AEs Leading to Withdrawal, and AEs of Special Interest (AESIs);Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs);Number of Participants with Unsolicited Adverse Events (AEs);Seroresponse Rate of Vaccine Recipients